| scholarly article | Q13442814 |
| P50 | author | Mark Linch | Q57304881 |
| P2093 | author name string | Monica Panca | |
| Nicholas Gough | |||
| Julian F Guest | |||
| Erikas Sladkevicius | |||
| P2860 | cites work | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population | Q30977332 | ||
| Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity | Q32073211 | ||
| Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma | Q33329951 | ||
| Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas | Q33333284 | ||
| Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. | Q33342842 | ||
| Phase II trial of gemcitabine in advanced sarcomas | Q33343208 | ||
| Safety and efficacy of ET-743: the French experience. | Q33343693 | ||
| Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma | Q33364342 | ||
| Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis | Q33370331 | ||
| Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas | Q33371392 | ||
| Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib | Q33387073 | ||
| Blood loss control with two doses of tranexamic Acid in a multimodal protocol for total knee arthroplasty | Q33450381 | ||
| Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group | Q33488674 | ||
| Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group | Q33490888 | ||
| High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? | Q33504061 | ||
| Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective | Q33629375 | ||
| Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma | Q34317458 | ||
| Resource consumption and costs of palliative care services in Spain: a multicenter prospective study | Q50108829 | ||
| New agents for the treatment of lymphoma. | Q50556470 | ||
| Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. | Q51114477 | ||
| Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. | Q51119082 | ||
| Modelling the resource implications of managing adults with Fabry disease in Italy. | Q51158499 | ||
| Routine outcome monitoring in clinical practice: service and non-service costs of psychiatric patients attending a Community Mental Health Centre in Italy. | Q51934841 | ||
| Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57570904 | ||
| Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group | Q57571575 | ||
| Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue | Q59305087 | ||
| A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma | Q67953440 | ||
| Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma | Q68801471 | ||
| Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial | Q69550800 | ||
| Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma | Q70611557 | ||
| High-dose ifosfamide in the treatment of advanced soft tissue sarcomas | Q71269016 | ||
| The cost of treating pancreatic cancer--a cohort study based on patients' records from four hospitals in Sweden | Q73641933 | ||
| A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas | Q73748188 | ||
| Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group | Q73862933 | ||
| Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the | Q74000597 | ||
| Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas | Q74118678 | ||
| Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) | Q77467836 | ||
| Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK) | Q77467839 | ||
| Gemcitabine in advanced stage soft tissue sarcoma: a phase II study | Q77878021 | ||
| [A blood transfusion in Sweden--the societal cost] | Q79291877 | ||
| Spanish recommendations on economic evaluation of health technologies | Q84078913 | ||
| Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and | Q34504714 | ||
| Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study | Q34506986 | ||
| Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients | Q34545931 | ||
| Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial | Q34554316 | ||
| ET-743: a novel agent with activity in soft tissue sarcomas | Q34562938 | ||
| Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. | Q34578099 | ||
| Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. | Q34580719 | ||
| Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. | Q34629449 | ||
| Dose-intensive chemotherapy in advanced adult soft tissue sarcoma | Q34734533 | ||
| ET-743: the US experience in sarcomas of soft tissues | Q34782126 | ||
| Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients | Q35676502 | ||
| Soft-tissue sarcomas in adults | Q36233720 | ||
| Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom | Q36731032 | ||
| Multidisciplinary management of metastatic sarcoma | Q37178308 | ||
| The management of soft tissue sarcoma | Q37335687 | ||
| Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain | Q37590299 | ||
| Therapeutic pipeline for soft-tissue sarcoma | Q37931268 | ||
| Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors | Q38612623 | ||
| Clinical and financial analysis of an acute palliative care unit in an oncological department. | Q39315581 | ||
| Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. | Q40385228 | ||
| Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. | Q40523631 | ||
| Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. | Q40627015 | ||
| Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. | Q40700785 | ||
| Nonreferral of possible soft tissue sarcomas in adults: a dangerous omission in policy | Q42159532 | ||
| Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. | Q42558870 | ||
| Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines | Q43059685 | ||
| Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution | Q43248980 | ||
| Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group | Q43582734 | ||
| Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients | Q43624652 | ||
| Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study | Q43686718 | ||
| Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation | Q43693204 | ||
| Epidemiology of soft tissue sarcomas in adults | Q43785904 | ||
| Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial | Q43791704 | ||
| Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. | Q43901434 | ||
| Health care costs for treatment of disseminated breast cancer | Q44239097 | ||
| Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis | Q44302437 | ||
| Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years | Q44382748 | ||
| Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. | Q44487130 | ||
| Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study | Q45196993 | ||
| Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. | Q45934667 | ||
| Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study | Q46658463 | ||
| An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma | Q46679624 | ||
| Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience | Q46758745 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | Sweden | Q34 |
| Italy | Q38 | ||
| P304 | page(s) | 725305 | |
| P577 | publication date | 2013-11-03 | |
| P1433 | published in | Sarcoma | Q26841949 |
| P1476 | title | Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden | |
| P478 | volume | 2013 |
| Q38448801 | Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study |
| Q57300477 | Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France |
| Q97884676 | Immunotherapy with nivolumab for the treatment of soft tissue sarcoma with pulmonary metastasis: A case report |
| Q91687113 | Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients |
| Q38872192 | Trabectedin for the treatment of soft tissue sarcomas. |
| Q55418407 | Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. |
Search more.